SynthesisThe Cochrane database of systematic reviews2016
Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.
Synthesis in The Cochrane database of systematic reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05340569 (Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma), which is not on this map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma: a Pilot Study.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effect of time to surgery in resectable pancreatic cancer: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2020Pooled it
- Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis.Medical oncology (Northwood, London, England) · 2017Pooled it
- Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis.Oncotarget · 2017Pooled it
- First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [European journal of nuclear medicine and molecular imaging · 2026Article
- Role of Preoperative Abdominal MRI in Preventing Futile Laparotomy or Diagnostic Staging Laparoscopy in the Setting of Pancreatic Adenocarcinoma.World journal of surgery · 2026Article
- Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma.Cancer medicine · 2026Article
- Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future.Updates in surgery · 2026Article
- Endoscopic Ultrasound-Lavage Technique for Pancreatic Cancer: An In Vivo Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Total non-division technique of pancreaticoduodenectomy: A strategic integration of superior mesenteric artery-first approach and total mesopancreas excision.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma.Molecular and clinical oncology · 2025Article
- Preoperative predictive factors for positive peritoneal cytology results in patients with pancreatic ductal adenocarcinomas: a retrospective study.International journal of clinical oncology · 2024Article
- Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.European journal of radiology open · 2024Article
- Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery.Current oncology (Toronto, Ont.) · 2024Review
- Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer.Cancers · 2024Review
- Review
- A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.Annals of surgical oncology · 2023Review
- Prognostic Impact of Positive Peritoneal Lavage Cytology on Resectable Pancreatic Body and Tail Cancer: A Retrospective Study.World journal of surgery · 2023Article
- Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer.Cancer medicine · 2023Article
- Article
- Surgical management of pancreatic ductal adenocarcinoma: a narrative review.Translational gastroenterology and hepatology · 2023Review
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
backgroundSurgical resection is the only potentially curative treatment for pancreatic and periampullary cancer. A considerable proportion of patients undergo unnecessary laparotomy because of underestimation of the extent of the cancer on computed tomography (CT) scanning. Laparoscopy can detect metastases not visualised on CT scanning, enabling better assessment of the spread of cancer (staging of cancer). This is an update to a previous Cochrane Review published in 2013 evaluating the role of diagnostic laparoscopy in assessing the resectability with curative intent in people with pancreatic and periampullary cancer.
objectivesTo determine the diagnostic accuracy of diagnostic laparoscopy performed as an add-on test to CT scanning in the assessment of curative resectability in pancreatic and periampullary cancer. SEARCH
methodsWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via PubMed, EMBASE via OvidSP (from inception to 15 May 2016), and Science Citation Index Expanded (from 1980 to 15 May 2016). SELECTION CRITERIA: We included diagnostic accuracy studies of diagnostic laparoscopy in people with potentially resectable pancreatic and periampullary cancer on CT scan, where confirmation of liver or peritoneal involvement was by histopathological examination of suspicious (liver or peritoneal) lesions obtained at diagnostic laparoscopy or laparotomy. We accepted any criteria of resectability used in the studies. We included studies irrespective of language, publication status, or study design (prospective or retrospective). We excluded case-control studies. DATA COLLECTION AND ANALYSIS: Two review authors independently performed data extraction and quality assessment using the QUADAS-2 tool. The specificity of diagnostic laparoscopy in all studies was 1 because there were no false positives since laparoscopy and the reference standard are one and the same if histological examination after diagnostic laparoscopy is positive. The sensitivities were therefore meta-analysed using a univariate random-effects logistic regression model. The probability of unresectability in people who had a negative laparoscopy (post-test probability for people with a negative test result) was calculated using the median probability of unresectability (pre-test probability) from the included studies, and the negative likelihood ratio derived from the model (specificity of 1 assumed). The difference between the pre-test and post-test probabilities gave the overall added value of diagnostic laparoscopy compared to the standard practice of CT scan staging alone. MAIN
resultsWe included 16 studies with a total of 1146 participants in the meta-analysis. Only one study including 52 participants had a low risk of bias and low applicability concern in the patient selection domain. The median pre-test probability of unresectable disease after CT scanning across studies was 41.4% (that is 41 out of 100 participants who had resectable cancer after CT scan were found to have unresectable disease on laparotomy). The summary sensitivity of diagnostic laparoscopy was 64.4% (95% confidence interval (CI) 50.1% to 76.6%). Assuming a pre-test probability of 41.4%, the post-test probability of unresectable disease for participants with a negative test result was 0.20 (95% CI 0.15 to 0.27). This indicates that if a person is said to have resectable disease after diagnostic laparoscopy and CT scan, there is a 20% probability that their cancer will be unresectable compared to a 41% probability for those receiving CT alone.A subgroup analysis of people with pancreatic cancer gave a summary sensitivity of 67.9% (95% CI 41.1% to 86.5%). The post-test probability of unresectable disease after being considered resectable on both CT and diagnostic laparoscopy was 18% compared to 40.0% for those receiving CT alone. AUTHORS'
conclusionsDiagnostic laparoscopy may decrease the rate of unnecessary laparotomy in people with pancreatic and periampullary cancer found to have resectable disease on CT scan. On average, using diagnostic laparoscopy with biopsy and histopathological confirmation of suspicious lesions prior to laparotomy would avoid 21 unnecessary laparotomies in 100 people in whom resection of cancer with curative intent is planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.